<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03044249</url>
  </required_header>
  <id_info>
    <org_study_id>MP-101-01</org_study_id>
    <nct_id>NCT03044249</nct_id>
  </id_info>
  <brief_title>A Study of MP-101 in Dementia-Related Psychosis and/or Agitation and Aggression</brief_title>
  <official_title>Tolerability, Pharmacokinetics, and Efficacy of MP-101 in the Treatment of Patients With Dementia-Related Psychosis and/or Agitation and Aggression</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mediti Pharma Inc.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mediti Pharma Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A ten-week study to assess MP-101 in Dementia-Related Psychosis and/or Agitation and
      Aggression
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 4, 2017</start_date>
  <completion_date type="Anticipated">January 2021</completion_date>
  <primary_completion_date type="Anticipated">January 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in the Neuropsychiatric Inventory (NPI) - Psychosis subscale</measure>
    <time_frame>Baseline up to 10 weeks</time_frame>
    <description>Change from baseline in the Neuropsychiatric Inventory (NPI) psychosis subscale that covers delusions and hallucinations, and/or in the agitation/aggression domain</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in the Clinical Global Impression of Improvement (CGI-I)</measure>
    <time_frame>Baseline up to ten weeks</time_frame>
    <description>Change from baseline in the Clinical Global Impression of Improvement (CGI-I)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in NPI Total Score</measure>
    <time_frame>Baseline up to 10 weeks</time_frame>
    <description>Change from baseline in NPI total score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in NPI Core Total Score</measure>
    <time_frame>Baseline up to 10 weeks</time_frame>
    <description>Combination of 3 items: hallucinations, delusions, and agitation/aggression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in NPI Caregiver Distress</measure>
    <time_frame>Baseline up to 10 weeks</time_frame>
    <description>Change from baseline in NPI caregiver distress</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in NPI Domains</measure>
    <time_frame>Baseline up to 10 weeks</time_frame>
    <description>Change from baseline in NPI domains of anxiety</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with any Treatment Emergent Adverse Event</measure>
    <time_frame>Baseline up to 11 weeks</time_frame>
    <description>Number of participants with untoward medical occurrences that emerge during the treatment period, having been absent pretreatment, or worsen relative to the pretreatment state, which do not necessarily have a causal relationship with this treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in the Unified Parkinson's Disease Rating Scale (UPDRS) Part III</measure>
    <time_frame>Baseline up to 10 weeks</time_frame>
    <description>Change from baseline in the Unified Parkinson's Disease Rating Scale (UPDRS) part III</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Population Pharmacokinetics: Plasma Levels of MP-101 and Metabolite</measure>
    <time_frame>Baseline up to 10 weeks</time_frame>
    <description>Parameters from weeks 2, 4, 6, 8 or 10, combined utilizing a population approach</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Psychosis</condition>
  <condition>Dementia</condition>
  <condition>Aggression</condition>
  <condition>Agitation</condition>
  <condition>Alzheimer Dementia</condition>
  <arm_group>
    <arm_group_label>MP-101</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Escalating dose administered orally once daily, starting at 20 milligrams up to 60 milligrams</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Administered orally once daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MP-101</intervention_name>
    <description>Capsules</description>
    <arm_group_label>MP-101</arm_group_label>
    <other_name>LY2979165</other_name>
    <other_name>LY2812223</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Capsules</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Females must be of non-childbearing potential, defined as women greater than or equal
             to (≥) 60 years of age, postmenopausal women ≥50 and less than(&lt;) 60 years of age who
             have had a cessation of menses for at least 12 months, or women who are congenitally
             or surgically sterile

          -  Males must agree to use 2 forms of highly effective birth control with female partners
             of childbearing potential while enrolled in the study, and for at least 28 days
             following the last dose

          -  Ambulatory (with or without walking device) with a stable gait

          -  Have an Mini-Mental State Examination (MMSE) score of 10 to 24

          -  Meet clinical criteria for one of the following disorders: dementia associated with
             Parkinson's disease, dementia with Lewy bodies, possible or probable Alzheimer's
             disease, frontotemporal degeneration spectrum disorders, vascular dementia

          -  Able to communicate verbally

          -  Have an NPI score of ≥4 on either individual item (delusions or hallucinations) or ≥6
             on the Psychosis Subscale (combined delusions and hallucinations), or an NPI score of
             ≥4 on agitation/aggression domain

          -  Have a reliable caregiver who provides written informed consent to participate and who
             is in frequent contact with the patient (defined as spending at least 4 hours/day at
             least 4 days/week with the patient and who is knowledgeable about the patient's
             daytime and nighttime behaviors). The caregiver must be able to communicate with site
             personnel, and opinion of the investigator, must understand the written
             protocol-specified questionnaires. If a caregiver cannot continue, one replacement
             caregiver will be allowed if the above criterion is met

          -  Must be on a stable dose of cholinesterase inhibitor and/or memantine, if applicable

          -  If taking antipsychotic drugs or any drug intended to treat psychosis, must be on a
             stable treatment regimen for ≥1 month prior to the study

          -  Have venous access sufficient to allow for blood sampling per the protocol

          -  Have clinical laboratory test results within normal reference range for the population
             or investigative site

          -  Are capable of participating in all study assessments

          -  Are able and willing to provide consent (patients and caregivers)

        Exclusion Criteria:

          -  Have a history of significant psychotic disorders (including, schizophrenia,
             delusional disorder, substance abuse psychosis that lasted over 6 months, major
             depressive disorder or bipolar disorder with psychotic episodes)

          -  Has a history of ischemic stroke within the last 12 months or any evidence of
             hemorrhagic stroke

          -  Have renal impairment as defined by Estimated Glomerular Filtration Rate (eGFR) &lt;45
             milliliters per minute per 1.73 square meters (ml/min/1.73m2)

          -  Have significant cardiovascular, respiratory, gastrointestinal, renal, hematologic, or
             oncologic comorbidities that could impact patient safety and study participation over
             10 weeks

          -  Have a history of seizures or other condition that would place the patient at
             increased risk of seizures.

          -  Are, in the investigator's judgment, at risk for suicide, or as indicated by the
             Columbia Suicide Severity Rating Scale (C-SSRS)

          -  Have a Fridericia's corrected QT interval (QTcF) greater than (&gt;) 450 milliseconds
             (ms) for males or 470 ms for females

          -  Are currently enrolled in any other clinical trial involving an investigational
             product or any other type of medical research judged not to be scientifically or
             medically compatible with this study

          -  Have participated, within the last 30 days, in a clinical trial involving an
             investigational product. If the previous investigational product has a long half-life,
             at least 3 months (or more) must have passed

          -  In the opinion of the investigator or sponsor, are unsuitable for inclusion in the
             study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mediti Pharma</last_name>
    <role>Study Director</role>
    <affiliation>Mediti Pharma Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Study Director</last_name>
    <email>choruspharma@lists.lilly.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Meridien Research</name>
      <address>
        <city>Brooksville</city>
        <state>Florida</state>
        <zip>34601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>James Andersen</last_name>
      <phone>352-597-8839</phone>
      <email>jandersen@meridienresearch.net</email>
    </contact>
    <investigator>
      <last_name>James Andersen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Galiz Research</name>
      <address>
        <city>Hialeah</city>
        <state>Florida</state>
        <zip>33016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jose Gamez</last_name>
      <phone>305-805-0921</phone>
      <email>jegamez@galizresearch.com</email>
    </contact>
    <investigator>
      <last_name>Jose Gamez</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Galiz Research</name>
      <address>
        <city>Miami Springs</city>
        <state>Florida</state>
        <zip>33166</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jose Gamez</last_name>
      <phone>305-820-3381</phone>
      <email>jegamez@galizresearch.com</email>
    </contact>
    <investigator>
      <last_name>Jose Gamez</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Parkinson's Disease Treatment Center of SW Florida</name>
      <address>
        <city>Port Charlotte</city>
        <state>Florida</state>
        <zip>33980</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ramon Gil</last_name>
      <phone>941-743-4987</phone>
      <email>dawnm@ParkinsonsFL.com</email>
    </contact>
    <investigator>
      <last_name>Ramon Gill, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Meridien Research Inc</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Florida</state>
        <zip>33709</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gigi Lefebvre</last_name>
      <phone>727-347-8839</phone>
      <email>glefebvre@meridienresearch.net</email>
    </contact>
    <investigator>
      <last_name>Gigi Lefebvre</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>J. Gary Booker, MD, Clinical Trials</name>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <zip>71104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>J G Booker</last_name>
      <phone>318-227-9600</phone>
      <email>drjgarybooker@bellsouth.net</email>
    </contact>
    <investigator>
      <last_name>J G Booker, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Alzheimer's Research Corporation</name>
      <address>
        <city>Manchester</city>
        <state>New Jersey</state>
        <zip>08759</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joshua Shua Haim</last_name>
      <phone>732-657-6100</phone>
      <email>shua-haim@comcast.net</email>
    </contact>
    <investigator>
      <last_name>Joshua Shua Haim</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Richmond Behavioral Associates</name>
      <address>
        <city>Staten Island</city>
        <state>New York</state>
        <zip>10312</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mark DiBuono</last_name>
      <phone>718-317-5522</phone>
      <phone_ext>3</phone_ext>
      <email>dibuono@rbany.com</email>
    </contact>
    <investigator>
      <last_name>Mark DiBuono</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>SKDS Research Inc.</name>
      <address>
        <city>Newmarket</city>
        <state>Ontario</state>
        <zip>L3Y 5G8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sam Henein</last_name>
      <phone>905-898-7582</phone>
    </contact>
    <investigator>
      <last_name>Sam Henein, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 31, 2017</study_first_submitted>
  <study_first_submitted_qc>February 2, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 6, 2017</study_first_posted>
  <last_update_submitted>May 24, 2018</last_update_submitted>
  <last_update_submitted_qc>May 24, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 25, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Psychotic Disorders</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dementia</mesh_term>
    <mesh_term>Alzheimer Disease</mesh_term>
    <mesh_term>Psychotic Disorders</mesh_term>
    <mesh_term>Mental Disorders</mesh_term>
    <mesh_term>Psychomotor Agitation</mesh_term>
    <mesh_term>Aggression</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

